Yearly Bisphosphonate!
September 20, 2006 on 1:38 pm | In Prescribing Extra - Drugs |
Print
|
An interim analysis of the HORIZON study was presented at the annual meeting of the American Society of Bone and Mineral Research.
The Health Outcomes and Reduced Incidence with Zoledronic acid Once yearly (Horizon) study aimed to assess the impact of an annual dose of zoledronic acid on the rate of fractures in postmenopausal women.
The complete data are not yet available however a press release claims that the early analysis shows that results appear promising for the drug.
The obvious major drawback is that the drug is formulated as an intravenous infusion and delivering it in primary care raises challenges.
Action: The investigated indication is currently unlicensed. If a licence extension is granted the challenges presented by intravenous administration are likely to significantly limit use.
Bookmark in del.icio.us